{"id":"glecaprevir-pibrentasvir-tablets","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5","effect":"Asthenia"}]},"_chembl":{"chemblId":"CHEMBL3545363","moleculeType":"Small molecule","molecularWeight":"838.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glecaprevir is a pangenotypic NS3/4A protease inhibitor that prevents HCV polyprotein processing. Pibrentasvir is a pangenotypic NS5A inhibitor that disrupts viral RNA replication and virion assembly. Together, they provide potent inhibition across all HCV genotypes with a high barrier to resistance.","oneSentence":"Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:06.310Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (all genotypes 1-6), treatment-naïve and treatment-experienced patients"},{"name":"Hepatitis C virus infection in patients with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT07040319","phase":"PHASE1, PHASE2","title":"Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-28","conditions":"Hepatitis C","enrollment":30},{"nctId":"NCT05637879","phase":"PHASE2, PHASE3","title":"Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder","status":"RECRUITING","sponsor":"White River Junction Veterans Affairs Medical Center","startDate":"2023-12-18","conditions":"PTSD","enrollment":92},{"nctId":"NCT04903626","phase":"PHASE3","title":"Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-08-24","conditions":"Hepatitis C Virus (HCV)","enrollment":286},{"nctId":"NCT05446857","phase":"PHASE2, PHASE3","title":"Glecaprevir/Pibrentasvir for the Treatment of PTSD","status":"COMPLETED","sponsor":"White River Junction Veterans Affairs Medical Center","startDate":"2023-04-01","conditions":"PTSD","enrollment":10},{"nctId":"NCT04042740","phase":"PHASE2","title":"Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-11-20","conditions":"Hepatitis C Infection, HIV Infection","enrollment":45},{"nctId":"NCT04682509","phase":"EARLY_PHASE1","title":"A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2022-03-20","conditions":"ESRD","enrollment":20},{"nctId":"NCT03981211","phase":"NA","title":"Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2021-02-12","conditions":"Hepatitis C, Liver Inflammation, Liver Cirrhoses","enrollment":60},{"nctId":"NCT03801707","phase":"PHASE2, PHASE3","title":"Utilization of Hepatitis C Positive Kidneys in Negative Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2019-03-22","conditions":"Kidney Transplant, Hepatitis C, HCV","enrollment":54},{"nctId":"NCT04577482","phase":"","title":"Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-07","conditions":"Hepatitis C Virus (HCV)","enrollment":42},{"nctId":"NCT03823911","phase":"PHASE4","title":"Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-18","conditions":"Cardiovascular Diseases, Hepatitis C, Hiv","enrollment":87},{"nctId":"NCT03067129","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Hepatitis C Virus (HCV)","enrollment":129},{"nctId":"NCT03625687","phase":"PHASE4","title":"Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-02-05","conditions":"Respiratory Failure, Hepatitis C","enrollment":19},{"nctId":"NCT02634008","phase":"PHASE3","title":"Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-06","conditions":"Hepatitis C, Acute","enrollment":83},{"nctId":"NCT04352309","phase":"","title":"Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-05-29","conditions":"Hepatitis C Virus (HCV)","enrollment":99},{"nctId":"NCT04596475","phase":"PHASE1, PHASE2","title":"Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-05-28","conditions":"Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of","enrollment":12},{"nctId":"NCT02939989","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-11-21","conditions":"Hepatitis C Virus Infection","enrollment":33},{"nctId":"NCT04614142","phase":"PHASE4","title":"Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2020-11-13","conditions":"End Stage Renal Disease, Chronic Hepatitis c","enrollment":""},{"nctId":"NCT03781726","phase":"PHASE4","title":"Multi-center Study to Transplant Hepatitis-C Infected Kidneys","status":"COMPLETED","sponsor":"Raymond Chung","startDate":"2019-04-10","conditions":"Renal Failure Chronic, Hepatitis C","enrollment":30},{"nctId":"NCT02966795","phase":"PHASE3","title":"A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-01-25","conditions":"Hepatitis C Virus (HCV)","enrollment":84},{"nctId":"NCT02640157","phase":"PHASE3","title":"A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus","enrollment":506},{"nctId":"NCT02243293","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-19","conditions":"Chronic Hepatitis C, Hepatitis C Virus","enrollment":694},{"nctId":"NCT02707952","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-22","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":295},{"nctId":"NCT02723084","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-08","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":136},{"nctId":"NCT02640482","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":304},{"nctId":"NCT02604017","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":703},{"nctId":"NCT02636595","phase":"PHASE3","title":"The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11","conditions":"Hepatitis C Virus","enrollment":121},{"nctId":"NCT02738138","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-05-17","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":153},{"nctId":"NCT02692703","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-22","conditions":"Chronic Hepatitis C, HCV, Hepatitis C Virus","enrollment":100},{"nctId":"NCT02243280","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-08","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":174},{"nctId":"NCT02642432","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-07","conditions":"Hepatitis C Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis","enrollment":146},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":89},{"nctId":"NCT03089944","phase":"PHASE3","title":"A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-28","conditions":"Hepatitis C Virus (HCV)","enrollment":343},{"nctId":"NCT03219216","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-06-06","conditions":"Hepatitis C Virus (HCV)","enrollment":100},{"nctId":"NCT03092375","phase":"PHASE3","title":"Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-04-20","conditions":"Hepatitis C, HCV","enrollment":177},{"nctId":"NCT03222583","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-04","conditions":"Hepatitis C Virus (HCV)","enrollment":546},{"nctId":"NCT03235349","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-09-29","conditions":"Hepatitis C Virus (HCV)","enrollment":160},{"nctId":"NCT03212521","phase":"PHASE3","title":"Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-07","conditions":"Hepatitis C Virus (HCV)","enrollment":230},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT04017338","phase":"PHASE3","title":"Transplantation Using Hepatitis C Positive Donors, A Safety Trial","status":"UNKNOWN","sponsor":"Jordan Feld","startDate":"2018-08-06","conditions":"Lung Transplant Infection, Heart Transplant Infection, Kidney Transplant Infection","enrollment":40},{"nctId":"NCT03623568","phase":"PHASE4","title":"Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant","status":"WITHDRAWN","sponsor":"Raymond T. Chung, MD","startDate":"2019-02-15","conditions":"Kidney Failure, Kidney Diseases, Hepatitis C","enrollment":""},{"nctId":"NCT03069365","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-28","conditions":"Hepatitis C Virus (HCV)","enrollment":101},{"nctId":"NCT02651194","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":104},{"nctId":"NCT02446717","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":141}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mavyret"],"phase":"marketed","status":"active","brandName":"glecaprevir/pibrentasvir tablets","genericName":"glecaprevir/pibrentasvir tablets","companyName":"Raymond T. Chung, MD","companyId":"raymond-t-chung-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication. Used for Chronic hepatitis C virus infection (all genotypes 1-6), treatment-naïve and treatment-experienced patients, Hepatitis C virus infection in patients with compensated cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}